Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,200,000 shares of common stock of Humanigen, Inc. The common stock is listed on the Nasdaq Capital Market under the symbol “HGEN.”

Humanigen, Inc. is a clinical stage biopharmaceutical company that is developing a portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases through its GM-CSF neutralization and gene-knockout platforms in order to reduce the inflammatory cascade associated with COVID-19, as well as CAR-T therapy-related side effects.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Jae Maeng and Prudence Ng. Partner David R. Bauer and associate Hilary Smith provided intellectual property advice. Counsel Ethan R. Goldman and associate Bree Gong provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

 

Copy link to share post